Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer

Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer

PurposeCombination strategies involving immune checkpoint inhibitors (ICIs) have been a prominent focus of research in the treatment of non-small cell lung cancer (NSCLC). Our prior findings demonstrated that the combination of autologous NK cells with the PD-1 antibody (Sintilimab), offered promisi...

Full description

Saved in:
Bibliographic Details
Main Authors: Lin Jia, Naifei Chen, Xiao Chen, Chao Niu, Ziling Liu, Kewei Ma, Lei Yang, Yuguang Zhao, Wei Song, Jin Lu, Chen Chen, Xiaofeng Cong, Xu Wang, Yinghui Xu, Guozhen Cui, Zengguang Liu, Rongrong Chen, Huan Yin, Na Zhang, Jiuwei Cui
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
non-small cell lung cancer
second line therapy
autologous NK cells
sintilimab
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1595382/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1595382/full

Similar Items